硝苯地平缓释片分别联用马来酸依那普利片与酒石酸美托洛尔片治疗高危高血压的临床疗效观察

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (10): 1167-1170.

硝苯地平缓释片分别联用马来酸依那普利片与酒石酸美托洛尔片治疗高危高血压的临床疗效观察

朱泓霞¹, 王雪锋¹, 徐倩²

¹ 余姚市第二人民医院药剂科,
² 余姚市人民医院,余姚 315400,浙江

收稿日期:2014-02-14 修回日期:2014-08-04 出版日期:2014-10-26 发布日期:2020-07-29
作者简介:朱泓霞,女,本科,主管药师,研究方向:心血管临床药学。Tel: 13486644218 E-mail: zhuyaoyan@gmail.com

Clinical comparative study on nifedipine sustained release tablets combined separately with enalapril maleate tablets and metoprolol tartrate tablets in treating high-risk hypertensive patients

ZHU Hong-xia¹, WANG Xue-feng¹, XU Qian²

¹ Department of Pharmacy,Yuyao City Second People's Hospital;
² Yuyao City People's Hospital,Yuyao 315400,Zhejiang ,China

Received:2014-02-14 Revised:2014-08-04 Online:2014-10-26 Published:2020-07-29

摘要/Abstract

摘要： 目的观察硝苯地平缓释片分别与马来酸依那普利片和酒石酸美托洛尔片治疗高危高血压的临床疗效和安全性。方法将确诊的130例高危高血压患者按照随机数字表法随机分为A组和B组,每组各65例。A组给予口服硝苯地平缓释片(20 mg, bid)和马来酸依那普利片(10 mg, qd),B组给予口服硝苯地平缓释片(20 mg, bid)和酒石酸美托洛尔片(100 mg, qd ),具体用量根据患者达标水平调节,疗程均为12个月,观察两组患者治疗前、后血压变化及不良反应发生情况,随访期间注意心脑血管事件发生等。结果 A组和B组的总有效率、血压达标率、心血管事件发生率分别为 90.48%、80.95%、14.28%和 87.50%、78.13%、15.62%,差异性比较均无统计学意义(P>0.05)。结论硝苯地平缓释片联用马来酸依那普利片和硝苯地平缓释片联用酒石酸美托洛尔片均可使高危高血压患者治疗达标,且安全性、耐受性好,依从性高。

关键词: 硝苯地平缓释片, 马来酸依那普利片, 酒石酸美托洛尔片, 高危高血压

Abstract: AIM: To compare the clinical efficacy and safety of influence of nifedipine sustained release tablets combined separately with enalapril maleate tablets and metoprolol tartrate tablets in the treatment of high-risk hypertension. METHODS: 130 cases diagnosed in high-risk hypertensive patients randomly divided into group A and group B, 65 cases in each group . Group A was given nifedipine sustained release tablets(20 mg, bid, p.o. ) and enalapril maleate tablets(10 mg, q.d., p.o. ), group B was given nifedipine sustained release tablets(20 mg, bid, p.o. ) and metoprolol tartrate tablets (100 mg, q.d., p.o.). The specific dosage adjustment of treatment based on patient compliance level. Two groups of patients were treated for 12 months. The changes of blood pressure and ADR were observed in 2 groups before and after treatment, and cardiovascular and cerebrovascular events out of the hospital.RESULTS: The total group A and group B efficiency rate , the blood pressure standard rate ,cardiovascular event rates were 90.48%, 80.95%, 14.28% and 87.50%, 78.13%, 15.62%, and showed no statistically significant difference (P>0.05). CONCLUSION: Nifedipine sustained release tablets combined with enalapril maleate tablets and nifedipine sustained release tablets combined with metoprolol tartrate tablets both can reach the treatment target,with safety, good tolerance,and high compliance.

Key words: nifedipine sustained release tablets, enalapril maleate tablets, metoprolol tartrate tablets, high-risk hypertension

中图分类号:

R544.1

朱泓霞, 王雪锋, 徐倩. 硝苯地平缓释片分别联用马来酸依那普利片与酒石酸美托洛尔片治疗高危高血压的临床疗效观察[J]. 中国临床药理学与治疗学, 2014, 19(10): 1167-1170.

ZHU Hong-xia, WANG Xue-feng, XU Qian. Clinical comparative study on nifedipine sustained release tablets combined separately with enalapril maleate tablets and metoprolol tartrate tablets in treating high-risk hypertensive patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1167-1170.

参考文献 11

[1]	王文. 第六届国际高血压及相关疾病学术研讨会纪要[J].高血压杂志,2004,12(6):490-491.
[2]	中国高血压防治指南修订委员会.中国高血压防治指南(2005修订版)[S].2005,3-39.
[3]	伍艳. 血管紧张素转化酶抑制剂加钙离子拮抗剂联合用药治疗模式对于轻、中度原发性高血压的临床疗效观察及其对血尿酸水平的影响[J].中国临床药理学与治疗学杂志,2011,16(3):317-321.
[4]	凌受毅,朱正芳,张卫国. 钙拮抗剂联合β受体阻滞剂治疗中青年高血压的疗效分析[J].中西医结合心血管病杂志,2012,10(9):1049-1050.
[5]	白雪垠,刘振兵. 非洛地平缓释片联合美托洛尔或依那普利治疗原发性高血压的疗效观察[J].实用心脑肺血管病杂志,2010,18(1):29-30.
[6]	陈源源,孙宁玲,张维忠,等. 评价非洛地平缓释片单药与以其为基础的联合降压方案对中国轻、中度原发性高血压患者的有效性、安全性及耐受性[J].北京大学学报:医学版,2007,39(6):619-623.
[7]	卢长彬,卜利,蔡杼颖,等. 贝那普利分别联合硝苯地平控释片与氢氯噻嗪治疗高危高血压患者的临床观察[J].中国医院药学杂志,2009, 29(16):1372-1374.
[8]	范书英,柯元南. 硝苯地平对高血压血管病变的改善作用[J].中华高血压杂志,2013,21(6):511-514.
[9]	林利展,唐东蕾. 抗高血压药物用药合理性的调查研究[J].中国医药指南,2013,11(17):5-6.
[10]	吴江,脱鸣富,雒晓科,等.抗高血压药联合用药分析[J].中国新药杂志,2012,21(1):96-99.
[11]	Bradley HA,Wiysonge CS,Volmink JA,et al.How strong is the evidence for of beta-blockers as first -line tllempy for hypertension? Systematicreview and meta analysis[J]. J Hypertens,2006,24(11):2131-2141.